Technical analysis indicates that selling in Oncosil (ASX: OSL) is overdone, likely driven in the past by the broader performance of the ASX and more recently by higher interest rates and inflation. However, the sell-off will taper soon as the chart suggests that selling could likely be overdone. This represents a very good buy opportunity for investors and with expansion and commercialization tend to continue in 2024, the stock could be gearing for a reversal.
Oncosil Nearing Inflection Point - Buy Signal
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 969800 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 700001 | 2 |
View Market Depth
| Last trade - 09.14am 22/05/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
Day chart unavailable